Publication:
A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines

Simple item page
dc.contributor.authorsTemel, M; Atagunduz, P; Direskeneli, H
dc.date.accessioned2022-04-25T00:10:17Z
dc.date.accessioned2026-01-11T13:26:59Z
dc.date.available2022-04-25T00:10:17Z
dc.date.issued2005
dc.identifier.doi10.1136/ard.2004.028423
dc.identifier.eissn1468-2060
dc.identifier.issn0003-4967
dc.identifier.pubmed16100352
dc.identifier.urihttps://hdl.handle.net/11424/263643
dc.identifier.wosWOS:000231208700035
dc.languageeng
dc.publisherBMJ PUBLISHING GROUP
dc.relation.ispartofANNALS OF THE RHEUMATIC DISEASES
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPLACEBO-CONTROLLED TRIAL
dc.subjectINFLIXIMAB
dc.subjectARTHRITIS
dc.subjectEFFICACY
dc.subjectAGENTS
dc.subjectSAFETY
dc.titleA major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines
dc.typeeditorial
dspace.entity.typePublication
oaire.citation.endPage1384
oaire.citation.issue9
oaire.citation.startPage1383
oaire.citation.titleANNALS OF THE RHEUMATIC DISEASES
oaire.citation.volume64

Files

Collections

Araştırma Çıktıları